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Specialty Update

What’s New in
Orthopaedic Research
BY MATTHEW J. SILVA, PHD, AND LINDA J. SANDELL, PHD

The last year has brought substantial advances in many areas
of orthopaedic research. Probably the most impressive is the
shift from a focus on implant design, obviously the most successful treatment of end-stage degenerative joint disease, to
the potential for earlier interventions, or “biological solutions,” that could increase the life of the cartilage, bone, tendons, and ligaments of the joint. The search for biological
solutions touches on all aspects of orthopaedic research: response to implant materials, development of tissue-engineered
cartilage and bone, and discovery of biomarkers for joint disease. We will review some of the latest advances made and
questions raised in this new age of orthopaedic research.
Implant Wear
This year’s combined Orthopaedic Research Society/American
Academy of Orthopaedic Surgeons symposium dealt with
clinical, engineering, and biological issues related to implant
wear. This symposium complemented a recent publication by
the Academy and the National Institutes of Health on implant
wear1. The manifestations of wear of total hip and knee replacements have been well documented in the past decade.
Most commonly, osteolysis progresses in a slow, “linear” fashion and is not detectable radiographically until five years or
more postoperatively, when periprosthetic radiolucent zones
may be observed. Rates of osteolysis as high as 60% have been
reported in association with certain hip implants2. In addition
to wear of hip and knee replacements, wear of total shoulder
and elbow replacements is an emerging problem that should
be carefully monitored in the future.
Biological Aspects of Wear—Osteolysis
Particle-induced osteolysis is a primary cause of aseptic loosening. A consensus has emerged that the predominant process
is one of cytokine production in response to phagocytosis of
implant wear particles resulting in increased proliferation and
differentiation of osteoclast precursors into mature osteo-

clasts. Several cell types, including macrophages, fibroblasts,
and osteoblasts, observed in periprosthetic tissues are believed
to play a role in the osteolytic process. Nevertheless, because
osteolysis ultimately involves bone resorption, investigators
have focused on understanding the role of the osteoclast. Recent breakthroughs in the understanding of osteoclast biology—namely, the roles of the OPG/RANKL/RANK system in
mediating osteoclast formation—have been directly relevant
to the current focus of osteolysis research.
The OPG/RANKL/RANK cytokine system is the predominant, final mediator of osteoclast formation3,4. This
system coordinates the interaction between osteoblasts
and osteoclasts that is necessary for differentiation of preosteoclasts (monocytes and macrophages) into mature, boneresorbing osteoclasts. RANK (receptor activator of nuclear
factor kappa B) is a transmembrane protein expressed on the
surface of pre-osteoclasts. RANKL (receptor activator of nuclear factor kappa B ligand, also known as TRANCE [tumor
necrosis factor {TNF}-related activation-induced cytokine]) is
produced by pre-osteoblastic stromal cells and immune cells.
When RANKL binds to RANK it initiates an intracellular
signaling cascade that activates, among others, the NF-κB
(nuclear factor kappa B) pathway and leads to osteoclast differentiation. RANKL, in the presence of macrophage colonystimulating factor (M-CSF), is sufficient and necessary for
osteoclast differentiation in vitro. The critical role of RANKLRANK binding in vivo is demonstrated by the fact that deletion of either gene results in severely osteopetrotic mice
devoid of osteoclasts. OPG (osteoprotegerin) is the third
member of the OPG/RANKL/RANK system. It is a secreted
decoy receptor (it lacks a transmembrane domain) that is
synthesized by pre-osteoblastic stromal cells and binds to
RANKL. OPG-RANKL binding blunts osteoclast differentiation; the critical role of OPG in regulating RANKL-induced
osteoclastogenesis is demonstrated by the fact that mice
lacking OPG have severe osteoporosis. In summary, pre-
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osteoblast/stromal cells can mediate osteoclast formation by
controlling the levels of available RANKL on the basis of the
ratio of OPG/RANKL. An increase in this ratio leads to increased OPG-RANKL binding and reduces the bioavailable
RANKL that is able to bind to RANK, thereby decreasing osteoclast differentiation. A decrease in this ratio leads to decreased OPG-RANKL binding and increased RANKL available
to bind to RANK and activate the critical pathway for formation of mature osteoclasts. Preliminary evidence that the
OPG/RANKL/RANK pathway is a critical factor in the development of clinical osteolysis has come from reports that detectable levels of messenger RNA for RANKL, RANK, and
OPG have been found in tissue adjacent to loose implants; additional studies with suitable control tissue are needed to confirm these observations.
Many upstream factors can influence osteolysis. Of
these factors, TNF-α is recognized as a critical cytokine in
mediating osteoclastogenesis following exposure to implant
particles. Using a model in which the calvariae of mice were
exposed to particles of implant materials (titanium, polymethylmethacrylate, etc.), several investigators demonstrated
that rapid osteoclastogenesis and bone erosion result as TNFα levels are increased. Recently, this process was shown to
occur through activation of the NF-κB intracellular pathway5,
indicating a link between the OPG/RANKL/RANK system,
TNF-α, and particle-induced osteolysis.
Therapeutic Targets in Osteolysis
Will the breakthroughs in the understanding of the biological
mechanisms of particle-induced osteolysis lead to drug treatments that can prevent periprosthetic bone loss? Anti-TNF
therapies may be effective for treating particle-induced osteolysis, as suggested by their success in treating rheumatoid
arthritis6. Anti-TNF treatment in the mouse calvarial model of
particle-induced osteolysis was shown to be only partially effective in blocking bone loss, a finding that was related to the
confounding effects of the adenovirus gene-delivery system
that was used7. Additional studies with nonviral delivery
methods are needed to determine the efficacy of anti-TNF
therapy. Promising early findings have been reported with use
of agents that target the OPG/RANKL/RANK system. Using
the mouse calvarial model, investigators from the University
of Rochester reported two approaches that were effective in reducing osteoclastogenesis and bone resorption: OPG gene
therapy and RANK blockade by a synthetic RANK fusion protein (RANK:Fc), both of which should work by increasing the
ratio of OPG/RANKL8. The same research group showed that
COX-2 (cyclooxygenase-2) plays a role in particle-induced osteolysis and that COX-2 inhibitors are therefore potential
therapeutic agents.
While agents to inhibit TNF-α or to alter the OPG/
RANKL ratio may ultimately prove to be beneficial for the
treatment of osteolysis, the use of bisphosphonates (which already have been established to be extremely effective in halting

osteoporotic bone loss) may provide a more timely option.
Several animal studies have demonstrated that not only can alendronate prevent particle-induced osteolysis but it can also
reverse bone loss in established osteolysis9. A recent clinical
trial demonstrated that administration of bisphosphonate in
the first six months after total hip replacement prevented
periprosthetic bone loss10. However, the bone loss observed in
the control group in this study was probably related to acute
effects of altered stress distribution or to surgical insult rather
than to particle-induced osteolysis. Nevertheless, taken together, these studies illustrate the potential of bisphosphonates for the treatment of osteolytic bone loss.
Engineering and Material Aspects of Wear
Submicrometer-sized polyethylene particles make up the bulk
of particulate wear debris found in periprosthetic tissues11.
Moreover, the incidence and severity of osteolysis have been
correlated with the amount of polyethylene wear. Thus, the
major research focus with regard to engineering has been to
understand the mechanical and material factors that influence polyethylene wear and to develop alternative processes
to improve the resistance of polyethylene to wear. In parallel,
there are continuing efforts to characterize and develop alternatives to the predominant metal-polyethylene bearing,
including metal-metal, ceramic-polyethylene, and ceramicceramic bearings.
Osteolysis is rare in patients with rates of acetabular
polyethylene wear of less than about 0.1 mm/yr, which is at
the lower end of the average reported range of wear rates, 0.1
to 0.2 mm/yr12. Thus, the “Holy Grail” of implant materials research and development has been to develop alternative polyethylenes that will reduce the average wear rate to below the
“osteolytic threshold.” Extensive work in the past five to ten
years has led to the widespread adoption of new processing
and sterilization protocols for polyethylene used in acetabular
components for total hip replacement. (It is likely that the
same or similar processes will soon be available for tibial components of total knee replacements.) While the details of the
processes differ among manufacturers12, the common goal is
to introduce a controlled, modest level of cross-linking while
avoiding the detrimental effects of oxidation. Radiation dose
determines the degree of cross-linking and in turn the resistance to wear. For the enhanced cross-linked polyethylenes
now available for acetabular components, manufacturers are
using radiation doses that have been reported to reduce the
rate of in vitro wear by ≥85% compared with that of nonirradiated polyethylene. The magnitude of wear reduction may
be lower for conditions of third-body wear, although crosslinking should still be beneficial.
A concern raised by some investigators is that the improvement in wear resistance resulting from elevated crosslinking comes at the expense of material strength and fracture
toughness. This concern has particular relevance to knee components, which historically have been more susceptible to
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fracture and fatigue-related damage such as delamination or
pitting. However, fatigue damage of polyethylene may be
largely attributable to reduced toughness caused by oxidative
damage that historically occurred because polyethylene components were sterilized by irradiation in air. Because oxidative
damage is minimized in the new polyethylenes, the reduction
in toughness due to cross-linking alone may be small enough
for fracture-related damage not to be an important clinical issue. However, only long-term clinical results will provide answers to the questions of whether elevated cross-linking of
polyethylenes will lower wear rates in vivo and, most importantly, whether it will reduce the incidence of osteolysis and
aseptic loosening.
Mouse Models in Orthopaedic Research
The increasingly routine use of murine models in musculoskeletal research represents a revolution that has taken place in
the last decade. Mouse studies are generally of two types. In
the first, the consequences of targeted mutations that delete
(knock out) or enhance (overexpress) the function of a particular gene are examined. The aim of these studies is to determine relationships between genetic structure and function,
and they may be useful for identifying the genetic basis of diseases linked to a single (or a few) genes. In the second type of
study, inbred strains of mice are examined in an attempt to
map quantitative phenotypic traits (e.g., obesity or bone density) to particular chromosomal regions13. Genetic analysis of
mother-daughter pairs and twins has indicated that bone
mineral density (the clinical standard for diagnosis of osteoporosis) is 50% to 70% heritable, and thus researchers have
been searching in mice for the gene (or, more likely, the genes)
that control phenotypic traits that might affect bone mineral
density (and other biomechanically relevant traits such as
bone size and strength). In either type of study, the choice of a
relevant phenotype (i.e., which traits will be examined) and
the techniques for assessing the phenotype are critical and will
be discussed.
Quantitative Genetics
While some discrete orthopaedic disorders can be linked to a
single genetic mutation, diseases in which risk is a continuous
variable (such as osteoporosis) are likely to be influenced by
multiple genes. Because osteoporosis is clinically diagnosed on
the basis of bone mineral density, studies in which the aim is
to find “osteoporosis genes” typically are based on the assessment of bone mineral density. One method for finding genes
that control bone mineral density is quantitative trait loci
mapping in mice derived by crossbreeding inbred mouse
strains. Mice within a given inbred strain (e.g., C57Bl/6J) are
essentially genetically identical and have a relatively narrow
distribution of quantitative traits like bone mineral density. By
crossbreeding two inbred strains that have different traits, an
F2 (second-generation) population can be created that has a
random mixture of alleles and a broader distribution of bone

mineral density. With the use of genetic markers, regions of
the chromosomes (i.e., quantitative trait loci) that are statistically associated with higher bone mineral densities in the F2
mice can be identified. A variation on this approach is to generate recombinant inbred strains by inbreeding a number of
the F2 mice; these mice can then be used for refined mapping
of the chromosomal regions of interest14. Most recently, congenic strains in which the quantitative trait loci from a donor
strain (e.g., a mouse with high bone mineral density) are
transferred to a recipient strain (e.g., a mouse with low bone
mineral density) have been developed to further assess
whether given quantitative trait loci contain a gene or genes
that regulate bone mineral density15. Together, these quantitative genetics approaches have been used to identify at least
twenty-eight quantitative trait loci for genes that control bone
mineral density in mice13. The large number of quantitative
trait loci identified to date may reflect the fact that bone mineral density is under the control of many interacting genes as
well as the fact that different investigators have used different
methods for assessing bone mineral density (e.g., assessment
of volumetric bone mineral density with peripheral quantitative computed tomography compared with assessment of areal
bone mineral density with dual-energy x-ray absorptiometry)
and have focused on different skeletal sites (the whole body,
the spine, the femur, etc.). The fact that different genes may
control bone mineral density at different skeletal sites highlights the complexity of the problem.
Functional Skeletal Phenotype
In recent years, there has been considerable debate about what
is the most relevant functional phenotype for gene-mapping
studies related to osteoporosis. As noted above, investigators
have focused on whole-bone or whole-body bone mineral
density because of the strong association between bone mineral density and fracture risk in humans. However, wholebone or whole-body bone mineral density in mice does not
necessarily relate to femoral neck or lumbar bone mineral
density in humans. Mouse bones, for example, contain a lower
proportion of trabecular bone than do human bones. More
recently, investigators have begun to focus on the “bottom
line” of skeletal function—i.e., whole-bone strength. To date,
most biomechanical phenotype studies have focused on testing long bones (e.g., femora) and thus have primarily assessed
cortical bone. Acceptable techniques for testing long bones include three-point and four-point bending and torsion16. Efforts to assess sites containing trabecular bone (e.g., vertebral
bodies and the femoral neck) have also been reported. Because
of the small size of mouse bones it is not possible to isolate
trabecular bone, and tests on specimens that contain both trabecular and cortical bone are likely to be the only practical option. To date, no particular testing technique has gained
widespread acceptance.
When functional skeletal phenotype is assessed, basic
principles of structural mechanics dictate that two types of
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data be obtained: whole-bone (structural) mechanical properties and bone geometric properties. Relevant whole-bone mechanical properties (for either bending or torsion of long
bones) include stiffness, yield load, ultimate load, post-yield
displacement, and energy to fracture. Relevant geometric
properties include cortical thickness, endosteal and periosteal
width, bone area, and bone moment of inertia. Ideally, a third
type of data—bone material properties (e.g., Young modulus
and ultimate tensile stress)—would be obtained from independent tests. In practice, it is difficult to directly assess material properties of mouse bones, and investigators typically
infer the “effective” material properties by using engineering
equations along with the whole-bone mechanical properties
and geometric properties. Armed with data on whole-bone
strength, size, and estimated material properties, investigators
are able to synthesize a relatively complete picture of the functional skeletal phenotype. However, numerous examples of incomplete phenotype assessment can be found in the literature.
In some cases, geometric data have been presented and used to
draw conclusions about skeletal strength in the absence of mechanical property data. The drawbacks of such an approach
are becoming more recognized17.
Functional Tissue-Engineering—
the Importance of Mechanical Loading
The development of tissue-engineered products and processes in the next decade will likely present an unprecedented
opportunity for clinicians to expand their treatment options
for such problems as repair of articular cartilage. Nevertheless,
many challenges must be overcome before successful longterm treatments can be made available. A workshop at this
year’s meeting of the Orthopaedic Research Society focused
attention on the need to better understand cellular mechanotransduction (i.e., how cells respond to physical stimuli) in
the context of both native and engineered tissues.
With regard to engineered tissues, in vitro physical
stimuli are relevant as a means to enhance biosynthetic activity and to promote the formation of a stiffer construct. Both
fluid flow and dynamic compression have been shown to increase matrix synthesis and enhance stiffness of cartilage
constructs18. Moreover, mechanical loading can enhance the
positive effects of biochemical stimuli. In engineered agarosechondrocyte constructs, dynamic loading over a five-week
period in conjunction with treatment with either transforming growth factor-β1 (TGF-β1) or insulin-like growth factor-1
(IGF-1) resulted in a synergistic enhancement of tissue stiffness that was greater than the sum of the effects of the two
stimuli applied separately19. This synergistic effect is consistent
with a similar effect observed in native cartilage explants and
suggests that the optimal process for producing functionally
competent constructs will require the coordinated delivery of
appropriate biochemical and biomechanical stimuli. At the
time of implantation, cartilage constructs should ideally have
mechanical properties approximating those of healthy native

tissue. In particular, the dynamic compressive modulus may
be the most important functional property because it will determine whether the tissue can sustain cyclic in vivo loading
without undergoing excessive strain leading to structural degradation and construct failure20. The concept of “functional
tissue-engineering” has been advocated to highlight that synthetic constructs must replace the mechanical function of the
native tissues21.
In addition to the use of mechanical loading to enhance
construct properties in vitro, the cells in the constructs should
be able to modulate their synthetic activity to reflect the in
vivo loading environment after implantation. One important
feature of native tissues (cartilage and bone) is that the cells
(chondrocytes and osteocytes) are surrounded by a pericellular matrix that differs from the bulk matrix. (Preliminary data
indicate that this is also true for tendon fibroblasts.) This pericellular matrix controls cell-matrix interactions and determines the microenvironment of the cell, including how the
bulk mechanical stresses and strains are transferred to the cell
surface. The peak strains at the chondrocyte-matrix interface
may be twice as high as the average tissue strain, whereas in
bone the cell strains may be an order of magnitude higher
than the average tissue strain. These relationships between the
cell and its surrounding matrix may be difficult to replicate in
engineered constructs. Cells seeded in artificial matrices may
not be as responsive to mechanical stimuli as are cells in native
tissue until they have synthesized a new pericellular matrix18.
The long-term success of engineered constructs will depend
largely on their ability to replicate cell-matrix interactions that
enable cells to respond appropriately to biophysical stimuli.
Development of Cartilage and Bone
Members of the TGF-β superfamily include the bone morphogenetic proteins (BMPs) and growth and differentiation
factors (GDFs). These potent signaling factors reside in the
extracellular matrix, can form gradients of morphogenetic
activity, or can signal to the cell to differentiate, proliferate, or
die. These growth factors stimulate the differentiation of cartilage and bone from uncommitted “stem” cells during organogenesis in the embryo and in fracture repair. They are also
important for the maintenance of cartilage and bone structure. These tissues have a great deal of extracellular matrix that
participates in the delivery and storage of growth factors. New
extracellular matrix molecules like chordin, noggin, and a specific domain of type-II procollagen bind to and consequently
participate in localizing and regulating the availability of the
growth factors.
Insights into the mechanism of bone and cartilage differentiation have been provided by a number of investigators
studying signal transduction and gene transcription. Rik
Derynk, a developmental biologist from the University of
California, San Francisco, reported new findings on the regulation of cartilage and bone development by TGF-β signaling.
Once free from binding proteins, TGF-β stimulates the ex-
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pression of cartilage-specific factors and at the same time
represses the bone-controlling transcription factor Cbfa1,
through control of a signal transduction protein, Smad3. The
differentiation of bone and that of cartilage appear to be mutually exclusive. This was also demonstrated with the transcription factor C/EBP. In independent studies, Jane Lian and
Gary Stein (University of Massachusetts Medical School,
Worcester, Massachusetts), investigating bone development,
and Ken Okazaki and one of us (L.J.S.) (Washington University School of Medicine, St. Louis, Missouri), investigating
cartilage development, discovered roles for C/EBP in the
regulation of bone-specific osteocalcin and cartilage-specific
CD-RAP, respectively. In bone, C/EBP acts as a positive factor
increasing expression of osteocalcin22, whereas in cartilage,
C/EBP acts as a negative regulatory factor for CD-RAP and
type-II collagen23. In fact, studies of transgenic mice have
shown that C/EBP is highly expressed in muscle and bone and
is responsible for inhibition of CD-RAP expression in those
tissues. Therefore, cells express a certain set of regulatory factors (e.g., the transcription factor Cbfa1 or C/EBP) that work
together to suppress one phenotype and to enhance another.
In this case, the same factor, Cbfa1, a positive regulator of
bone gene expression, is turned off during cartilage differentiation, and high levels of C/EBP enhance bone gene expression and repress cartilage gene expression.
Yet another new molecule has been found to be necessary for bone differentiation: Osterix24. This molecule was
found during a screen for bone-specific proteins and, when
“knocked out” in mice, no bone was formed. The transcription factor Osterix appears to act downstream of the transcription factor Cbfa1.
Molecular Biology of Fracture Repair
For the last few years, investigators in this area have begun to
take a molecular view of fracture-healing. Taking advantage
of the ability to induce fractures in small animals that was
pioneered by Thomas Einhorn (Boston Medical Center, Boston, Massachusetts), researchers have used a combination of
histology, in situ hybridization to mRNA, and immunohistochemistry to provide a molecular description of events
taking place within the tissue. Currently, the focus is on the
use of these models to study factors that may affect bonehealing. Various methods to augment bone-healing with use
of BMPs, VEGF (vascular endothelial growth factor), and
bisphosphonates have been tested and have shown various
capacities to improve the rate of healing. Of critical importance is the effect of the new selective nonsteroidal antiinflammatory drugs, the COX-2 inhibitors, on bone-healing.
These inhibitors are widely used to control pain in a variety of
musculoskeletal conditions, and they account for forty-five
million prescriptions in the United States alone25. Leonelli et
al.25 reported that rats given the COX-2 inhibitor rofecoxib
were more likely to have a nonunion, a malunion, and a larger
callus than were controls and rats treated with ibuprofen.

Goodman et al.26 supported these findings by showing that a
COX-2 inhibitor also inhibited bone ingrowth in an experimental model.
The Genetic Basis for Orthopaedic
Diseases is Beginning to Emerge:
Lessons from Fruit Flies and Nematodes
While the study of fruit flies and nematodes will never be popular in orthopaedic research laboratories, a growing appreciation of the basic mechanisms of development has arisen from
the study of more primitive organisms. Research on multiple
hereditary exostosis is a good example of how developmental
biologists and scientists interested in human disease can complement each others’ investigations. The primary insight regarding the mechanism of this human disease came from
studying a disease in the fruit fly (Drosophila) called toutvelu, in which there is a defect in signaling of the hedgehog
protein. Signaling of the hedgehog protein is disrupted because of a mutation in the enzyme necessary for synthesis of a
proteoglycan that binds to the hedgehog protein for distribution. In a workshop entitled Genetics of Orthopaedic Disorders,
Chair Chris Evans stressed the recent headway made in understanding the genes involved in controlling some musculoskeletal diseases. Multiple hereditary exostosis is characterized by
osseous outgrowths at the margins of the growth plate. Jacqueline Hecht (University of Texas Medical School, Houston,
Texas) presented data showing that the genes that cause multiple hereditary exostosis, called EXT1 and EXT2, encode for
polymerase enzymes that form the heparin sulfate carbohydrates on proteoglycans. The heparin sulfate proteoglycans are
involved in the control of chondrocyte differentiation by regulation of growth-factor stimulation. In this case, the likely protein that is misregulated, and causes the growth of exostoses, is
the hedgehog protein. Abnormal signaling of the hedgehog
protein, known to be an important regulator of growth-plate
function, causes further differentiation of growth-plate chondrocytes into hypertrophic chondrocytes, which then can be
mineralized and replaced by bone generated from osteoblasts
in the vasculature.
Another unforeseen molecular player, the heparin
sulfate proteoglycan perlecan, is now known to participate
in skeletal dysplasia of the Silverman-Handmaker type27. In
fact, while 60% of mice missing this proeoglycan have the
dysplasia, 40% die during embryogenesis because of defective
cephalic development. It is very possible that the responsible
signaling events are the same as those in multiple hereditary
exostosis, as described above.
The understanding of rare diseases will help to provide
information that can be applied to all musculoskeletal diseases. Although individually rare, the many different forms,
taken together, result in a substantial number of affected individuals with major morbidity and mortality. The rapid advances in the understanding of the molecular basis for skeletal
dysplasias have made the classification of diseases difficult. For
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example, the clinical symptoms of diseases caused by type-IIcollagen mutations can be quite varied; they cannot be classified only according to the molecular defect. Therefore, a
new classification of genetic disorders of the skeleton has
been proposed28. In this system, there is a nosology—a catalog
of defined entities. This includes a clinical classification,
focused on age-specific presentations and clinical signs,
to be of help in the diagnostic approach, and a molecularpathogenetic classification based on the genes and pathogenetic mechanisms involved. These two classifications will be
cross-correlated in an electronic database.
Stem Cells
The use of stem cells in research has become a household discussion. Stem cells have a pluripotent ability to commit to
specific cell fates. Such flexibility is apparent in the embryonic
stem cell, which by definition is a precursor of all cells in the
developed organism. It is less apparent that many other tissues
have a reserve of “stem” cells with limited but distinct potential, such as periosteal and perichondrial cells, pericytes from
blood vessels, stem cells from muscle and fat, and, potentially
the richest adult source, bone-marrow stem cells. The use of
these cells and the conditions under which they can differentiate have been intensively investigated recently. Muscle, fat, and
mesenchymal stem cells from bone marrow can be induced to
form bone. While it has been known for a while that BMPs
stimulate bone differentiation, Majumdar et al.29, from Genetics Institute, showed that BMP-2 or BMP-9 together with a
relatively new cytokine, IL-11 (interleukin-11), function to
promote chondrogenesis in these cells. IL-11 is a member of
the IL-6 family and has been found to be effective in prevention of inflammatory bowel disease.
Gene Therapy
Bone
The advantage of gene therapy is that when the gene is resident in the cell, the products of gene expression can be made
and distributed in situ. This therapy may be applied to cells
while they are in the body (in vivo) or to cells or pieces of tissue that have been removed from the body (ex vivo). More
than fifty papers on this valuable technique were presented at
the meeting of the Orthopaedic Research Society in 2002. Although none are used yet in the clinical setting, the induction
of bone formation through gene therapy may be on the horizon. In addition to studies involving the growth factors BMP2 and BMP-7 (OP-1), the induction of bone with use of LIM
mineralization protein-1 appears to be feasible30. LIM mineralization protein-1 is a transcription factor that may function
through stimulation of endogenous BMPs. While the methods
of gene delivery have not been well defined, the exogenous delivery of genes known to stimulate repair or replacement of
bone will likely become a common method for stimulation of
cell metabolism. In a novel technique, muscle stem cells were
used to deliver BMP-4 in a nonhealing skull defect. The gene

for BMP-4 was cloned into a retrovirus and transduced into
the muscle cells ex vivo, after which the cells were implanted
into the defect31. Use of the retrovirus holds promise as a safe
method in humans as it is not antigenic and therefore provides a low immunological risk to the patient.
Other Skeletal Tissues
Adenoassociated virus vectors are being used to transduce human meniscal cells and even meniscal explants in vitro. The
efficiency of transduction has been quite high, and future experiments will likely focus on the delivery of specific genes.
IGF-1 gene therapy has proved productive for inducing healing of cartilage in horses and, in conjunction with dynamic
loading, in bovine cartilage discs. The use of BMP-2 and
BMP-4 for induction of cartilage-healing has been examined
as has gene expression of BMP-2 and other growth factor
genes in nucleus pulposus.
Osteoarthritis and Biomarkers
Great headway continues to be made in the understanding of
matrix degradation in osteoarthritis. The recent discovery of
specific “aggrecanases” and “versicanases” has revealed the
participation of an entire group of enzymes that cleave proteoglycans in tissue. These enzymes, in addition to the matrix
metalloproteinases that have been studied for decades, may be
responsible for the initial cleavages in the important proteoglycans. Recently, the attention of investigators has turned
to the factors that are responsible for activation of these destructive enzymes and how they might function in vivo. Controversial at this point is the timing of degradation by specific
enzymes during the course of progression of osteoarthritis
and which molecules are initially targeted. Resolution of the
control of these pathways will be the focus of the next few
years of research as headway is made in understanding the
progression of osteoarthritis.
Recognition that osteoarthritis progresses slowly over a
long period has stimulated research into methods of detection of the stage of osteoarthritis and the potential for prediction of short and long-term outcomes. Certainly, if the disease
can be better defined, interventional therapies short of joint
replacement could be developed and implemented. Various
methods are being used to determine the state of cartilage and
the rate of disease progression. Mechanical, imaging, and biological parameters are under investigation. Camacho et al.32
are using a fiberoptic probe for detection of degenerative
cartilage, while others are using pressure probes to detect
mechanical changes in the cartilage, or serum markers for collagen and aggrecan metabolism. With one promising method,
changes in the rate of synthesis are compared with the rate of
degradation so that when repair slows down and degradation
increases, the molecular changes can be monitored in urine
and serum over time, predicting the rate of cartilage loss33.
Finally, as there have been so many advances in orthopaedic research recently, the reader is referred for further in-
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depth study to the Transactions of the Orthopaedic Research Society, which are available on the web site www.ors.org, and as a
CD-ROM containing the abstracts, available from the Society
by telephone (847-698-1625).
NOTE: The authors thank Clark Hung, Chris Jacobs, Farsh Guilak, Tom Brown, Harry McKellop, John
Clohisy, Yousef Abu-Amer, and Jacqueline Hecht for their helpful input in preparing this review.

Matthew J. Silva, PhD
Linda J. Sandell, PhD
Department of Orthopaedic Surgery, Washington University School
of Medicine at Barnes-Jewish Hospital, Mail Stop 90-34-674, 216

South Kingshighway, St. Louis, MO 63110. E-mail address for M.J.
Silva: silvam@msnotes.wustl.edu. E-mail address for L.J. Sandell:
sandelll@msnotes.wustl.edu
The authors did not receive grants or outside funding in support
of their research or preparation of this manuscript. They did not
receive payments or other benefits or a commitment or agreement
to provide such benefits from a commercial entity. No commercial
entity paid or directed, or agreed to pay or direct, any benefits to
any research fund, foundation, educational institution, or other
charitable or nonprofit organization with which the authors are
affiliated or associated.

References
1. Wright TM, Goodman SB, editors. Implant wear in total joint replacement:
clinical and biological issues, material and design considerations. Rosemont,
IL: American Academy of Orthopaedic Surgeons; 2001.
2. Harris WH. Wear and periprosthetic osteolysis: the problem. Clin Orthop.
2001;393:66-70.
3. Aubin JE, Bonnelye E. Osteoprotegerin and its ligand: a new paradigm for regulation of osteoclastogenesis and bone resorption. Osteoporos Int. 2000;11:
905-13.
4. Khosla S. Minireview: the OPG/RANKL/RANK system. Endocrinology. 2001;
142:5050-5.
5. Clohisy JC, Teitelbaum S, Chen S, Erdmann JM, Abu-Amer Y. Tumor necrosis
factor-alpha mediates polymethylmethacrylate particle-induced NF-kappaB activation in osteoclast precursor cells. J Orthop Res. 2002;20:174-81.
6. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden
JR, Smolen JS, Weisman M, Emery P, Feldmann M, Harriman GR, Maini RN.
Infliximab and methotrexate in the treatment of rheumatoid arthritis. AntiTumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy
Study Group. N Engl J Med. 2000;343:1594-602.
7. Childs LM, Goater JJ, O’Keefe RJ, Schwarz EM. Effect of anti-tumor necrosis
factor-alpha gene therapy on wear debris-induced osteolysis. J Bone Joint
Surg Am. 2001;83:1789-97.
8. Childs LM, Paschalis EP, Xina LP, Dougall WC, Anderson D, Boskey AL, Puzas JE, Rosier RN, O’Keefe RJ, Boyce BF, Schwarz EM. In vivo RANK signaling blockade using the receptor activator of NF-kappaB:Fc effectively prevents
and ameliorates wear debris-induced osteolysis via osteoclast depletion without inhibiting osteogenesis. J Bone Miner Res. 2002;17:192-9.
9. Millett PJ, Allen MJ, Bostrom MP. Effects of alendronate on particle-induced
osteolysis in a rat model. J Bone Joint Surg Am. 2002;84:236-49.
10. Wilkinson JM, Stockley I, Peel NF, Hamer AJ, Elson RA, Barrington NA, Eastell R. Effect of pamidronate in preventing local bone loss after total hip arthroplasty: a randomized, double-blind, controlled trial. J Bone Miner Res.
2001;16:556-64.
11. Jacobs JJ, Roebuck KA, Archibeck M, Hallab NJ, Glant TT. Osteolysis: basic
science. Clin Orthop. 2001;393:71-7.
12. McKellop HA. Bearing surfaces in total hip replacements: state of the art and
future developments. Instr Course Lect. 2001;50:165-79.
13. Rosen CJ, Beamer WG, Donahue LR. Defining the genetics of osteoporosis:
using the mouse to understand man. Osteoporos Int. 2001;12:803-10.
14. Klein OF, Carlos AS, Vartanian KA, Chambers VK, Turner EJ, Phillips TJ,
Belknap JK, Orwoll ES. Confirmation and fine mapping of chromosomal regions influencing peak bone mass in mice. J Bone Miner Res. 2001;16:
1953-61.
15. Shimizu M, Higuchi K, Kasai S, Tsuboyama T, Matsushita M, Mori M,
Shimizu Y, Nakamura T, Hosokawa M. Chromosome 13 locus, Pbd2, regulates bone density in mice. J Bone Miner Res. 2001;16:1972-82.
16. Brodt MD, Ellis CB, Silva MJ. Growing C57Bl/6 mice increase whole bone
mechanical properties by increasing geometric and material properties. J
Bone Miner Res. 1999;14:2159-66.
17. van der Meulen MC, Jepsen KJ, Mikic B. Understanding bone strength: size
isn’t everything. Bone. 2001;29:101-4.
18. Guilak F, Setton LA. Functional tissue engineering and the role of biochemi-

cal signaling in articular cartilage repair. Unpublished data.
19. Mauck RL, Seyhan SL, Jamieson KV, Nicoll SB, Ateshian GA, Hung CT. Synergistic effects of growth factors and dynamic loading for cartilage tissue engineering. Read at the Annual Meeting of the Orthopaedic Research Society;
2002 Feb 10-13; Dallas, TX.
20. Ateschian GA, Hung CT. Functional properties for articular cartilage in tissue
engineered constructs. Unpublished data.
21. Guilak F, Butler DL, Goldstein SA. Functional tissue engineering: the role of
biomechanics in articular cartilage repair. Clin Orthop. 2001;391 Suppl:
S295-305.
22. Banerjee C, Javed A, Choi JY, Green J, Rosen V, van Wijnen AJ, Stein JL,
Lian JB, Stein GS. Differential regulation of the two principal Runx2/Cbfa1
n-terminal isoforms in response to bone morphogenetic protein-2 during
development of the osteoblast phenotype. Endocrinology. 2001;142:
4026-39.
23. Okazaki K, Li J, Sandell LJ. C/EBP beta is involved in the regulation of tissue
specific expression of cartilage-derived retinoic acid-sensitive protein. Read
at the Annual Meeting of the Orthopaedic Research Society; 2002 Feb 1013; Dallas, TX.
24. Nakashima K, Zhou X, Kunkel G, Zhang Z, Deng JM, Behringer RR, de Crombrugghe B. The novel zinc finger-containing transcription factor Osterix is required for osteoblast differentiation and bone formation. Cell. 2002;108:17-29.
25. Leonelli S, Goldberg B, Safanda J, Bagwe M, King S. The effect of cyclooxygenase 2 (COX-2) inhibitors on bone healing. Read at the Annual Meeting of
the Orthopaedic Research Society; 2002 Feb 10-13; Dallas, TX.
26. Goodman SB, Ma T, Ikenoue T, Matsura I, Trindade M, Fox N, Wang N, Genovese M, Smith RL. COX-2 selective NSAID decreases bone ingrowth in vivo.
Read at the Annual Meeting of the Orthopaedic Research Society; 2002 Feb
10-13; Dallas, TX.
27. Arikawa-Hirasawa E, Watanabe H, Takami H, Hassel JR, Yamada Y. Perlecan is
essential for cartilage and cephalic development. Nat Genet. 1999;23:354-8.
28. Superti-Furga A, Bonafe L, Rimoin DL. Molecular-pathogenetic classification
of genetic disorders of the skeleton. Am J Med Genet. 2001;106:282-93.
29. Majumdar MK, Wang E, Morris EA. Interleukin 11 synergizes with BMP-9 in
promoting chondrogenic differentiation of human multipotential mesenchymal cells. Read at the Annual Meeting of the Orthopaedic Research Society;
2002 Feb 10-13; Dallas, TX.
30. Minamide A, Boden S, Titus L, Hair G, Oliver C, Viggeswarapu M. 2002
Mechanism of bone formation induced by AD-LMP-1: Histological and immunohistochemical studies. Read at the Annual Meeting of the Orthopaedic Research Society; 2002 Feb 10-13; Dallas, TX.
31. Wright V, Peng H, Usas A, Cummins J, Gearhart B, Shen HC, Huard J. Bone
healing in immunocompetent mice by retroviral BMP4 transduced muscle
stem cells. Read at the Annual Meeting of the Orthopaedic Research Society;
2002 Feb 10-13; Dallas, TX.
32. Camacho N, West P, Yang X, Lin J, Bostrom M. An infrared fiber optic probe
for detection of degenerative cartilage. Read at the Annual Meeting of the Orthopaedic Research Society; 2002 Feb 10-13; Dallas, TX.
33. Garnero P, Ayral X, Rousseau J-C, Christgau S, Sandell LJ, Dougados M,
Delmas PD. Uncoupling of type II collagen synthesis and degradation predicts
progression of joint damage in patients with knee osteoarthritis. Unpublished
data.

